80761-61-1

Basic information

• Product Name: 3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo- (9CI)
• Synonyms: 3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo- (9CI)
• CAS NO: 80761-61-1
• Molecular Formula: C10H6ClNO2
• Molecular Weight: 207.61314
• Product Categories: ACIDHALIDE
• Mol File: 80761-61-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo- (9CI)(80761-61-1)
• EPA Substance Registry System: 3-Quinolinecarbonyl chloride, 1,4-dihydro-4-oxo- (9CI)(80761-61-1)

Safety Data

• Hazardous Substances Data: 80761-61-1(Hazardous Substances Data)

Usage

Uses

1,4-Dihydro-4-oxo-3-quinolinecarbonyl Chloride is an intermediate in synthesizing Ivacaftor Carboxylic Acid (I940605). It is an impurity of Ivacaftor (I940600); a drug used in the treatment of cystic fibrosis.

Upstream product

• 13721-01-2 4-oxo-1,4-dihydroquinoline-3-carboxylic acid 

Downstream Products

• 857208-58-3 4-oxo-1,4-dihydroquinoline-3-carboxylic acid phenylamide 
• 873054-73-0 N-(4-ethylphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 873054-36-5 N-(4-isopropylphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 873050-50-1 4-oxo-1,4-dihydroquinoline-3-carboxylic acid (1H-indol-6-yl)amide 

Relevant articles and documents

Quinolone-based oxazolidinone compound as well as preparation method and application thereof

The invention discloses a quinolone-based oxazolidinone compound with a formula (HB), a solvate thereof, a stereoisomer of the compound, or a pharmaceutically acceptable salt of the compound, a preparation method of the compound and application of the com

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.